Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
13 hedge funds and large institutions have $20M invested in Anebulo Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0.01% more ownership
Funds ownership: 28.18% → 28.18% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $21M → $20M (-$1.02M)
13% less funds holding
Funds holding: 15 → 13 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$72.4K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.02K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$165 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$33 |
| 5 |
JP Morgan Chase
New York
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$72.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.67K |
| 3 |
BlackRock
New York
|
-$731 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$413 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$178 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $14.6M | – | – | – |
|
|
LA
2
LVW Advisors
Pittsford,
New York
| $1.75M | – | – | – |
|
|
NCM
3
Nantahala Capital Management
New Canaan,
Connecticut
| $1.4M | – | – | – |
|
4
Morgan Stanley
New York
| $1.09M | – | – | – |
|
|
IC
5
Ikarian Capital
Dallas,
Texas
| $431K | – | – | – |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $420K | +$1.02K | +401 | +0.3% |
|
|
7
Geode Capital Management
Boston,
Massachusetts
| $140K | +$72.4K | +28,531 | +125% |
|
|
BFM
8
Boothbay Fund Management
New York
| $51.8K | – | – | – |
|
|
9
BlackRock
New York
| $10.3K | -$731 | -288 | -7% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $9.01K | -$4.67K | -1,838 | -36% |
|
|
11
Bank of America
Charlotte,
North Carolina
| $177 | +$165 | +65 | New |
|
|
12
JP Morgan Chase
New York
| $27 | +$3 | +1 | +11% |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$72.5K | -25,253 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$413 | -144 | Closed |
|
|
15
Wells Fargo
San Francisco,
California
| – | -$178 | -62 | Closed |
|
|
16
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$33 | +13 | +34% |
|
ANEB Hedge Fund Activity: Q2 2024 in Review
13 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q2 2024, worth a combined $20M — down 4.9% from $21M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ANEB and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Geode Capital Management, adding an estimated $72.4K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $72.5K sold.
- 13 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q2 2024, down from 15 in Q1 2024.
- Funds reported $20M of Anebulo Pharmaceuticals stock for Q2 2024, down 4.9% quarter-over-quarter.
- 1 fund opened new Anebulo Pharmaceuticals positions in Q2 2024 and 3 closed out, a net change of -2 holders.
- The largest Anebulo Pharmaceuticals buyer in Q2 2024 was Geode Capital Management, an estimated $72.4K added.
- The largest Anebulo Pharmaceuticals seller in Q2 2024 was Susquehanna International Group, an estimated $72.5K sold.
Based on aggregated 13F filings for Q2 2024.